Subcortical Atrophy Is Associated with Cognitive Impairment in Mild Parkinson Disease: A Combined Investigation of Volumetric Changes, Cortical Thickness, and Vertex-Based Shape Analysis

References

1. 1.↵
   2. Muslimovic D,
   3. Post B,
   4. Speelman JD, et al

   . Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005;65:1239–45

   CrossRef
2. 2.↵
   2. Sollinger AB,
   3. Goldstein FC,
   4. Lah JJ, et al

   . Mild cognitive impairment in Parkinson's disease: subtypes and motor characteristics. Parkinsonism Relat Disord 2010;16:177–80

   CrossRefPubMed
3. 3.↵
   2. Poletti M,
   3. Emre M,
   4. Bonuccelli U

   . Mild cognitive impairment and cognitive reserve in Parkinson's disease. Parkinsonism Relat Disord 2011;17:579–86

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Kandiah N,
   3. Narasimhalu K,
   4. Lau PN, et al

   . Cognitive decline in early Parkinson's disease. Mov Disord 2009;24:605–08

   CrossRefPubMed
5. 5.↵
   2. Caviness JN,
   3. Driver-Dunckley E,
   4. Connor DJ, et al

   . Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007;22:1272–77

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Litvan I,
   3. Aarsland D,
   4. Adler CH, et al

   . MDS task force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord 2011;26:1814–24

   CrossRefPubMed
7. 7.↵
   2. Bronnick K,
   3. Ehrt U,
   4. Emre M, et al

   . Attentional deficits affect activities of daily living in dementia-associated with Parkinson's disease. J Neurol Neurosurg Psychiatry 2006;77:1136–42

   Abstract/FREE Full Text
8. 8.↵
   2. Aarsland D,
   3. Bronnick K,
   4. Ehrt U, et al

   . Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 20062007;78:36–42
9. 9.↵
   2. Levy G,
   3. Tang MX,
   4. Louis ED, et al

   . The association of incident dementia with mortality in PD. Neurology 2002;59:1708–13

   CrossRef
10. 10.↵
    2. Owen AM

    . Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry. Neuroscientist 2004;10:525–37

    Abstract/FREE Full Text
11. 11.↵
    2. Calabresi P,
    3. Picconi B,
    4. Parnetti L, et al

    . A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. Lancet Neurol 2006;5:974–83

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Pan PL,
    3. Shi HC,
    4. Zhong JG, et al

    . Gray matter atrophy in Parkinson's disease with dementia: evidence from meta-analysis of voxel-based morphometry studies. Neurol Sci 2013;34:613–19

    CrossRefPubMed
13. 13.↵
    2. Almeida OP,
    3. Burton EJ,
    4. McKeith I, et al

    . MRI study of caudate nucleus volume in Parkinson's disease with and without dementia with Lewy bodies and Alzheimer's disease. Dement Geriatr Cogn Disord 2003;16:57–63

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Burton EJ,
    3. McKeith IG,
    4. Burn DJ, et al

    . Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 2004;127:791–800

    Abstract/FREE Full Text
15. 15.↵
    2. Junqué C,
    3. Ramirez-Ruiz B,
    4. Tolosa E, et al

    . Amygdalar and hippocampal MRI volumetric reductions in Parkinson's disease with dementia. Mov Disord 2005;20:540–44

    CrossRefPubMed
16. 16.↵
    2. Summerfield C,
    3. Junque C,
    4. Tolosa E, et al

    . Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol 2005;62:281–85

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Bouchard TP,
    3. Malykhin N,
    4. Martin WR, et al

    . Age and dementia-associated atrophy predominates in the hippocampal head and amygdala in Parkinson's disease. Neurobiol Aging 2008;29:1027–39

    CrossRefPubMedWeb of Science
18. 18.↵
    2. Nishio Y,
    3. Hirayama K,
    4. Takeda A, et al

    . Corticolimbic gray matter loss in Parkinson's disease without dementia. Eur J Neurol 2010;17:1090–97

    CrossRefPubMed
19. 19.↵
    2. Tessa C,
    3. Giannelli M,
    4. Della Nave R, et al

    . A whole-brain analysis in de novo Parkinson disease. AJNR Am J Neuroradiol 2008;29:674–80

    Abstract/FREE Full Text
20. 20.↵
    2. Pereira JB,
    3. Ibarretxe-Bilbao N,
    4. Marti MJ, et al

    . Assessment of cortical degeneration in patients with Parkinson's disease by voxel-based morphometry, cortical folding, and cortical thickness. Hum Brain Mapping 2012;33:2521–34

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Tinaz S,
    3. Courtney MG,
    4. Stern CE

    . Focal cortical and subcortical atrophy in early Parkinson's disease. Mov Disord 2011;26:436–41

    CrossRefPubMed
22. 22.↵
    2. Ibarretxe-Bilbao N,
    3. Junque C,
    4. Segura B, et al

    . Progression of cortical thinning in early Parkinson's disease. Mov Disord 2012;27:1746–53

    CrossRefPubMed
23. 23.↵
    2. Patenaude B,
    3. Smith SM,
    4. Kennedy DN, et al

    . A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage 2011;56:907–22

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Gelb DJ,
    3. Oliver E,
    4. Gilman S

    . Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33–39

    CrossRefPubMedWeb of Science
25. 25.↵
    Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003;18:738–50

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Hoehn MM,
    3. Yahr MD

    . Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427–42

    CrossRefPubMed
27. 27.↵
    2. Tomlinson CL,
    3. Stowe R,
    4. Patel S, et al

    . Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649–53

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Folstein MF,
    3. Robins LN,
    4. Helzer JE

    . The Mini-Mental State Examination. Arch Gen Psychiatry 1983;40:812

    CrossRefPubMedWeb of Science
29. 29.↵
    2. Dalrymple-Alford JC,
    3. MacAskill MR,
    4. Nakas CT, et al

    . The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010;75:1717–25

    CrossRef
30. 30.↵
    2. Litvan I,
    3. Goldman JG,
    4. Tröster AI, et al

    . Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012;27:349–56

    CrossRefPubMed
31. 31.↵
    2. Rosen WG,
    3. Mohs RC,
    4. Davis KL

    . A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356–64

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Dubois B,
    3. Slachevsky A,
    4. Litvan I, et al

    . The FAB: a frontal assessment battery at bedside. Neurology 2000;55:1621–26

    CrossRefPubMed
33. 33.↵
    2. Sunderland T,
    3. Hill JL,
    4. Mellow AM, et al

    . Clock drawing in Alzheimer's disease: a novel measure of dementia severity. J Am Geriatr Soc 1989;37:725–29

    PubMedWeb of Science
34. 34.↵
    2. Jenkinson M,
    3. Beckmann CF,
    4. Behrens TE, et al

    . FSL. Neuroimage 2012;62:782–90

    CrossRefPubMedWeb of Science
35. 35.↵
    2. Gelineau-Morel R,
    3. Tomassini V,
    4. Jenkinson M, et al

    . The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis. Hum Brain Mapping 2012;33:2802–14

    CrossRefPubMed
36. 36.↵
    2. Zivadinov R,
    3. Heininen-Brown M,
    4. Schirda CV, et al

    . Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage 2012;59:331–39

    CrossRefPubMedWeb of Science
37. 37.↵
    2. Batista S,
    3. Zivadinov R,
    4. Hoogs M, et al

    . Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. J Neurol 2012;259:139–46

    CrossRefPubMedWeb of Science
38. 38.↵
    2. Hughes EJ,
    3. Bond J,
    4. Svrckova P, et al

    . Regional changes in thalamic shape and volume with increasing age. Neuroimage 2012;63:1134–42

    CrossRefPubMedWeb of Science
39. 39.↵
    2. Fischl B

    . FreeSurfer. Neuroimage 2012;62:774–81

    CrossRefPubMedWeb of Science
40. 40.↵
    2. Genovese CR,
    3. Lazar NA,
    4. Nichols T

    . Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 2002;15:870–78

    CrossRefPubMedWeb of Science
41. 41.↵
    2. Lyoo CH,
    3. Ryu YH,
    4. Lee MS

    . Topographical distribution of cerebral cortical thinning in patients with mild Parkinson's disease without dementia. Mov Disord 2010;25:496–99

    CrossRefPubMed
42. 42.↵
    2. Melzer TR,
    3. Watts R,
    4. MacAskill MR, et al

    . Grey matter atrophy in cognitively impaired Parkinson's disease. J Neurol Neurosurg Psychiatry 2012;83:188–94

    Abstract/FREE Full Text
43. 43.↵
    2. Song SK,
    3. Lee JE,
    4. Park HJ, et al

    . The pattern of cortical atrophy in patients with Parkinson's disease according to cognitive status. Mov Disord 2011;26:289–96

    CrossRefPubMed
44. 44.↵
    2. Dalaker TO,
    3. Zivadinov R,
    4. Larsen JP, et al

    . Gray matter correlations of cognition in incident Parkinson's disease. Mov Disord 2010;25:629–33

    CrossRefPubMed
45. 45.↵
    2. Herrero MT,
    3. Barcia C,
    4. Navarro JM

    . Functional anatomy of thalamus and basal ganglia. Childs Nerv Syst 2002;18:386–404

    CrossRefPubMedWeb of Science
46. 46.↵
    2. de la Monte SM,
    3. Wells SE,
    4. Hedley-Whyte T, et al

    . Neuropathological distinction between Parkinson's dementia and Parkinson's plus Alzheimer's disease. Ann Neurol 1989;26:309–20

    CrossRefPubMedWeb of Science
47. 47.↵
    2. de Jong LW,
    3. van der Hiele K,
    4. Veer IM, et al

    . Strongly reduced volumes of putamen and thalamus in Alzheimer's disease: an MRI study. Brain 2008;131:3277–85

    Abstract/FREE Full Text
48. 48.↵
    2. Kassubek J,
    3. Juengling FD,
    4. Ecker D, et al

    . Thalamic atrophy in Huntington's disease co-varies with cognitive performance: a morphometric MRI analysis. Cereb Cortex 2005;15:846–53

    Abstract/FREE Full Text
49. 49.↵
    2. Benedict RH,
    3. Hulst HE,
    4. Bergsland N, et al

    . Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients. Mult Scler 2013;19:1478–84

    Abstract/FREE Full Text
50. 50.↵
    2. Goldenberg G,
    3. Schuri U,
    4. Gromminger O, et al

    . Basal forebrain amnesia: does the nucleus accumbens contribute to human memory? J Neurol Neurosurg Psychiatry 1999;67:163–68

    Abstract/FREE Full Text
51. 51.↵
    2. de Jong LW,
    3. Wang Y,
    4. White LR, et al

    . Ventral striatal volume is associated with cognitive decline in older people: a population based MR-study. Neurobiol Aging 2012;33:424.e1–10

    CrossRefPubMed
52. 52.↵
    2. van Beilen M,
    3. Leenders KL

    . Putamen FDOPA uptake and its relationship to cognitive functioning in PD. J Neurol Sci 2006;248:68–71

    CrossRefPubMed
53. 53.↵
    2. Zarei M,
    3. Ibarretxe-Bilbao N,
    4. Compta Y, et al

    . Cortical thinning is associated with disease stages and dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2013;84:875–81

    Abstract/FREE Full Text
54. 54.↵
    2. Lee HM,
    3. Kwo KY,
    4. Kim MJ, et al

    . Subcortical grey matter changes in untreated, early stage Parkinson's disease without dementia. Parkinsonism Relat Disord 2014;20:622–26

    CrossRefPubMed
55. 55.↵
    2. Rinne JO,
    3. Mlic JR,
    4. Paljärvi L, et al

    . Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 1989;26:47–50

    CrossRefPubMedWeb of Science